Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 16/20 | 0.34 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.33 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.33 |
| ▸ | TGFB1 | P01137 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17645358 | 0.93 | TGFBR1 (0.39) | TGFBR1TGFB1 | |
| SCHEMBL17645458 | 0.86 | TGFBR1 (0.33) | TGFBR1 | |
| SCHEMBL17645420 | 0.84 | PROKR1 (0.32) | TGFBR1 | |
| SCHEMBL17671339 | 0.79 | LRRK2 (0.37) | TGFBR1ACVR2ATGFBR2PRMT5WDR77 | |
| SCHEMBL28667903 | 0.79 | TGFBR1 (0.39) | TGFBR1TGFB1 | |
| SCHEMBL17645167 | 0.78 | TGFBR1 (0.57) | TGFBR1TGFB1 | |
| SCHEMBL17645265 | 0.76 | TGFBR1 (0.41) | TGFBR1TGFB1 | |
| SCHEMBL22165910 | 0.74 | TGFBR1 (0.44) | TGFBR1TGFB1 | |
| SCHEMBL22186419 | 0.72 | TGFBR1 (0.59) | TGFBR1TGFB1 | |
| SCHEMBL17671340 | 0.71 | LRRK2 (0.41) | TGFBR1TGFB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204377-B1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2018-09-26 | — | — | EP | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | TGFBR1, TGFBR2, PDGFRB | TGFBR1 1/4885ACVR2A 67/4885TGFBR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.